Forte Biosciences Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing a live biotherapeutic FB-401
that has completed Phase 1/2a clinical trial to treat inflammatory skin diseases for pediatric atopic dermatitis patients. The company was incorporated in 2007 and is based in Torrance, California. The company trades on NCM exchange. The company headquarter is located in Torrance, United States. The company was established in the 2007.
| Ticker | FBRX |
| Long Name | Forte Biosciences, Inc. |
| Short Name | Forte Biosciences, Inc. |